REFERENCES
1. Jin XH, Zheng KI, Pan KH, Xie YP, Zheng MH. COVID-19 in a patient with chronic lymphocytic leukaemia. Lancet Haematol . 2020;7(4):e351-e352. doi:10.1016/S2352-3026(20)30074-0
2. Paneesha S, Pratt G, Parry H, Moss P. Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia.Leuk Res . 2020;93:106366. doi:10.1016/j.leukres.2020.106366
3. Cuneo A, Scarfo L, Reda G, et al. CHRONIC LYMPHOCYTIC LEUKEMIA MANAGEMENT IN ITALY DURING THE COVID-19 PANDEMIC. A CAMPUS CLL REPORT.Blood . June 2020. doi:10.1182/blood.2020006854
4. Favresse J, Eucher C, Elsen M, et al. Unexpected kinetics of anti-SARS-CoV-2 total antibodies in two patients with chronic lymphocytic leukemia. Br J Haematol . 2020;n/a(n/a). doi:10.1111/bjh.16954
5. Perini GF, Fischer T, Gaiolla RD, et al. How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation. Hematol Transfus Cell Ther . 2020. doi:10.1016/j.htct.2020.04.002
6. Di Ciaccio P, McCaughan G, Trotman J, et al. Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic.Intern Med J . 2020;50(6):667-679. doi:10.1111/imj.14859